Inhibitors of selectin functions in the treatment of inflammatory skin disorders

Michael P Schön
Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine and Department of Dermatology, Julius-Maximilians-University, Würzburg, Germany

Abstract: Selectins mediate tethering and rolling of leukocytes to the vascular endothelium, the first adhesive step in the recruitment of immune cells to inflamed tissues. Thus, selectins play a key role in the pathogenesis of common inflammatory skin disorders such as atopic dermatitis or psoriasis. As a consequence of their key functions, selectins have received much attention as potential target structures for new therapies. Indeed, a number of agents including small-molecule as well as peptide compounds interfering with selectin functions have been developed to treat inflammatory disorders. However, many of the selectin-directed compounds have not held up to the high expectations, in some cases due to overlapping and mutually compensating functions of selectins or suboptimal pharmacokinetic properties of the compounds, while other agents appear to be more promising candidates and have already entered clinical trials. Selectively targeting the functions of one or several selectins involved in the cascade of leukocyte recruitment promises exciting new therapeutic options, but, at the same time, bears considerable imponderables, which will be discussed in this review article.

Keywords: lymphocyte recruitment, adhesion molecules, chemokines, inflammation, target molecules, selectins

Introduction
Recruitment of lymphocytes in a tissue-specific fashion is, on the one hand, a requirement for immune surveillance and defense against pathogens and tumors, but, on the other hand, plays a key role in the pathogenesis of inflammatory diseases, such as psoriasis, eczematous disorders, drug-induced eruptions, or lichen planus of the skin (Groves and Kupper 1996; Robert and Kupper 1999). Consequently, insight into mechanisms of leukocyte recruitment to the skin is essential not only for our understanding of the pathophysiology of inflammatory skin disorders, but also for the development of novel and selective therapies to treat such diseases, which heavily impact quality of life as well as the economic burden of healthcare systems worldwide. Given that the first steps of tissue-selective trafficking of leukocytes are mediated primarily by selectins, these molecules are being explored as promising therapeutic target structures.

Tethering and rolling of leukocytes: the selectin-mediated first contact to the vessel wall
The first steps of leukocyte localization to all tissues include tethering and rolling along the vessel wall (Figure 1) – rather loose and transient adhesive interactions that are essential for the subsequent firm adhesion, activation, and transmigration (von Andrian and Mackay 2000). Members of the selectin family of adhesion molecules are the primary mediators of these initial contacts (Groves et al 1991; Shimizu et al 1991; von Andrian et al 1991; Smith et al 1993; Springer 1994; Butcher...
Selectins are single-chain transmembrane adhesion molecules, which have been named for their lectin-like domain that attaches to carbohydrate ligands presented on glycoprotein scaffolds (Varki 1994; Feizi 2001; Ley 2001). Three selectins have been described: E- and P-selectin are expressed by endothelial cells, and L-selectin is expressed by leukocytes. E-selectin (CD62E) is primarily regulated on the transcriptional level and is strongly induced upon activation of endothelial cells by proinflammatory stimuli (Cotran and Gimbrone 1986; Bevilacqua and Stengelin 1989). In contrast, P-selectin (CD62P) is rapidly mobilized to the cell surface from its storage vesicles, the cytoplasmic Weibel-Pallade bodies, upon activation of endothelial cells (Bonfanti and Furie 1989; McEver and Beckstead 1989). In addition, there is some transcriptional regulation of P-selectin (Ulbrich et al 2003). The pivotal role of P- and E-selectin for lymphocyte rolling has been demonstrated in a large variety of experimental approaches interfering with adhesive interactions of selectins and their carbohydrate ligands (Carlos and Harlan 1994; Todderud et al 1997). Of note, several studies have demonstrated considerably overlapping and mutually compensating functions of the selectin family members, a finding that raises important consequences and constraints for the rational design of selectin-blocking drugs (Labow et al 1994; Jung and Ley 1999; Weninger et al 2000; Collins et al 2001). Consistent with these studies, a function-blocking antibody specifically directed against E-selectin did not significantly alleviate psoriasis, one of the most common chronic inflammatory skin disorders, in a clinical trial (Bhushan et al 2002). Likewise, specifically blocking L-selectin in a recent controlled clinical trial has failed to improve psoriatic lesions (Hardtke et al 2005). These observations in clinical settings have strongly supported and complemented the results from experimental studies showing that some selectin-mediated functions may be redundant and that interfering with a single selectin alone is not sufficient to interrupt the inflammatory chains in some inflammatory diseases. This notion is further corroborated by several small-molecule compounds that interfere with the functions...
of more than one selectin. The list of such compounds includes efomycine M, a non-carbohydrate macrolide inhibitor of both E- and P-selectin functions. Blocking both E- and P-selectin by efomycine M significantly diminished rolling of leukocytes on cutaneous microvessels and markedly alleviated chronic inflammatory skin conditions in a T cell-mediated murine model of psoriasis as well as in human psoriatic skin transplanted onto scid/scid mice (Schön et al 2002). Another promising example exhibiting broader activity against all three known selectins is bimosiamose, a compound that appeared to be efficacious in early clinical trials (Aydt and Wolff 2002–2003; Hicks et al 2005). Likewise, broader clinical efficacy may be expected from some other recently described compounds interfering with the functions of more than one selectin (Boehncke and Schön 2003; Ulbrich et al 2003).

The lymphocyte-expressed L-selectin (CD62L) binds to endothelial cell selectin ligands (Figure 1). Although some of its ligands, such as PNAd (Peripheral Node Addressin), may be induced in chronic inflammatory skin disorders, the contribution of L-selectin to cutaneous recruitment of lymphocytes appears to be limited due to its preferential expression by naive and a subpopulation of memory T cells rather than activated T cells. Thus, it has been proposed that L-selectin/PNAd interactions may be more important for extravasation of naive T cells in lymph nodes (von Andrian and Mempel 2003; Ley and Kansas 2004), a prerequisite for the priming of naive T lymphocytes. The topographic distribution of L-selectin at the tips of microvilli of rolling lymphocytes is thought to be important for easy contact formation with endothelial ligands (Fors et al 2001). Following ligand binding, L-selectin is shed from the cell surface at the trailing edge of rolling lymphocytes. The shedding of L-selectin is a proteolytic process mediated by metalloproteases (Condon et al 2001; Zhao et al 2001). It is thought that shedding is required for proper lymphocyte rolling (Hafezi-Moghadam and Ley 1999), since inhibition of L-selectin shedding resulted in increased LFA-1/ICAM-1-mediated firm adhesion and, consecutively, transmigration of lymphocytes (Hafezi-Moghadam et al 2001), supporting the hypothesis of a regulatory function of the shedding process.

In addition to the expression of L-selectin, lymphocytes express transmembrane glycoproteins bearing Sialyl-LewisX (sLeX) moieties, that function as E- and P-selectin ligands (Varki 1994). Among these ligands, the sLeX-bearing CLA (cutaneous lymphocyte-associated antigen), a specially glycosylated form of PSGL-1 (P-selectin glycoprotein ligand-1, CD162) (Fuhlbrigge et al 1997), is preferentially expressed by lymphocytes localizing to the skin. Accumulating experimental evidence has been published demonstrating that CLA is indeed functionally involved in tissue-specific recruitment to this organ (Picker et al 1990, 1991). Topographic specialization of microvascular endothelial cells within the skin is suggested by the observation that CLA-bearing T lymphocytes appear to extravasate preferentially through the endothelium of the superficial dermal plexus (Kunstfeld et al 1997), a cutaneous compartment potentially accessible for topically applied selectin inhibitors.

Selectin-mediated rolling of lymphocytes is complemented by VLA-4 (very late-activation antigen-4, CD49d/CD29), a heterodimeric adhesion receptor of the integrin family that binds to VCAM-1 (vascular cell adhesion molecule-1) and MAdCAM-1 (mucosal addressin cell adhesion molecule-1), two members of the immunoglobulin (Ig) superfamily of adhesion molecules (Figure 1). It has been reported that VLA-4 also mediates rolling of leukocyte subsets under certain conditions (Berlin et al 1995; Reinhardt et al 1997; Singbartl et al 2001). It is thought that its involvement in lymphocyte rolling is due, at least in part, to the topographic presentation of VLA-4 on microvilli of rolling cells, similar to the decoration of L-selectin, thus enabling easy contact formation with endothelial cell-expressed counter-receptors (Berlin et al 1995). The ligand binding affinity of VLA-4 can be rapidly up-regulated via the p56 lck Src kinase signaling pathway following T lymphocyte stimulation (Feigelson et al 2001). This rapid change in integrin activity is thought to be crucial for the transition from rolling to firm adhesion of lymphocytes. While some aspects of the interplay of VLA-4- and selectin-mediated adhesive interactions involved in lymphocyte rolling still remain to be unraveled, it appears that there is some redundancy in their functions.

In cutaneous inflammation in rats, all three receptors, E-selectin, P-selectin, and VLA-4, are apparently required for rolling of memory T lymphocytes (Issekutz AC and Issekutz TB 2002). It is possible that tissue-specific (micro)-environmental factors regulate their relative contributions to lymphocyte recruitment. In addition to VLA-4, the integrin LFA-1 has been reported to mediate neutrophil rolling under certain conditions (Henderson et al 2001), and both VLA-4 and LFA-1 can mediate selectin-independent recruitment of neutrophils and monocytes to sites of chronic inflammation (Birner et al 2000). Fractalkine may be another player contributing to endothelial capture and firm adhesion...
of leukocytes without an involvement of selectins (Fong et al 1998; Haskell et al 2000).

Finally, in addition to rolling of lymphocytes through direct contact to the endothelial lining, recent research has highlighted the importance of platelets for rolling under certain conditions (Klinger and Jelkmann 2002; Liu and Kubes 2003). While P-selectin has been implicated in adhesive interactions of platelets and leukocytes, the exact contribution of this process to cutaneous inflammation has not been completely defined yet (Geng et al 2004; Ludwig et al 2004).

**Selectins as molecular targets for antiinflammatory therapies**

Given that selectins mediate the critical first step in the cascade of leukocyte recruitment during inflammatory responses, it is not surprising that these molecules have received much attention as potential target structures for selective and specific therapies. Indeed, few areas in biomedical and pharmaceutical research reflect the excitement and enthusiasm, but also a number of drawbacks and disappointments associated with new developments as vividly as selectin-directed antiinflammatory strategies targeting lymphocyte extravasation. Indeed, as they appear to meet the “desire” for a mechanistic basis of diseases and, consecutively, rational therapeutic strategies, selectins are appealing target structures (Boehncke and Schön 2003; Schön et al 2003). This is reflected by a variety of selectin-directed agents including small-molecule compounds, carbohydrate mimetics, and antibodies generated by several companies to treat inflammatory disorders (synopsis shown in Table 1). However, a closer look at the complex and intertwined molecular crosstalk underlying lymphocyte recruitment may dampen some illusions or dishearten overenthusiastic approaches. In addition, recruitment to inflamed tissues may be tightly connected with other cellular functions of immunocytes such as chemokine receptor-mediated activation that follows selectin-mediated adhesion. As a consequence, inflammatory diseases encountered by clinicians are rarely predictable from single molecular pathways, and the design or selection of compounds targeting specific molecules involved in the inflammatory cascade is often difficult and may face considerable imminent problems (Kaila and Thomas 2002). This is reflected by the fact that some of the programs searching for inhibitors of the selectin family have been stopped for the indication of inflammatory disorders (Table 1), a notion that may reflect inherent difficulties in targeting this very initial step of leukocyte recruitment.

Overall, there are several challenges that may make approaches to target molecules involved in leukocyte recruitment very complex and unpredictable, and this is mirrored by the fact that some of the previous approaches were not satisfying in preclinical or clinical trials. This includes trials using the sialyl LewisX-mimetic Cylexin (Kerr et al 2000), an anti E-selectin-directed monoclonal antibody (Blushan et al 2002), or a L-selectin-directed antibody (Hardtke et al 2005). Several reasons, which are not mutually exclusive, can be delineated:

1. Specificity for only one selectin or a suboptimal combination of selectin specificities;
2. Low IC$_{50}$ values;

### Table 1 Selectin-directed compounds developed for the treatment of inflammatory disorders

| Target | Compound | Company | Status       | Reference                                 |
|--------|----------|---------|--------------|------------------------------------------|
| Selectins | CY-1503 | Cytel Corp | Preclinical | Kerr et al 2000                          |
| Selectins | BMS-190394 | BMS | Preclinical | Binrbaum et al 1997                      |
| Selectins | OC-229648 | Ontogen Kaneko | Preclinical | Marinier et al 2001                      |
| Selectins | efomycine M | none | Preclinical | Schön et al 2002                          |
| E-selectin | ESA-2 | Novartis | Preclinical | Thomson et al 1993; Bantely and Ernst 2001; Hafezi-Moghadam et al 2001; Biedermann et al 2002 |
| Selectins | OJ- R9188 | Nippon Organon | Preclinical | Ikekami-Kuzuhara et al 2001 |
| Selectins | TBC-1269 | Texas Biotechnology Revotar | Preclinical | Abraham et al 1999; Anaya-Prado et al 2002 |
| E- and P-selectin | PS3 | None | Preclinical | Yvin et al 2002 |
| E- and P-selectin | EP-SC7 | Protein Design Labs | Phase I | Berg et al 1995; Alon et al 1998 |
| E- and L-selectin | EL-246 | LygoCyte | Preclinical | Carraway et al 1998 |
| E-selectin | CDP-850 | Celltech | Phase II | Bhushan et al 2002 |
| P-selectin | rhPSGL-1 Ig | Genetics Institute | Phase II | Khor et al 2000 |
| L-selectin | LD201t1 | WyethNeXStar | Preclinical | Hicie et al 1996 |
3. Short half-lives or other unfavorable pharmacokinetic properties; or
4. Lability of selectin–selectin ligand interaction, which is essential for short-lived lymphocyte–endothelial interactions.

So, what are the challenges that we are facing? Perhaps the most important reason for the limited predictability of antiinflammatory approaches through targeting selectins is functional redundancy; i.e., as outlined above, selectins may have considerable functional overlaps. In particular, this is true for endothelial E- and P-selectin (Labow et al 1994; Jung and Ley 1999; Collins et al 2001), allowing them to compensate for each other in case of loss of function of one of the players. While prominent examples have been reported in the selectin field (Labow et al 1994; Jung and Ley 1999; Collins et al 2001), this problem is by no means unique to this family, since similar (maybe even more pronounced) redundancy problems are faced when targeting the chemokine/chemokine receptor system (Zlotnik and Yoshie 2000; Onuffer and Horuk 2002).

It was long believed that CLA expressed by skin-homing T cells is mainly an E-selectin ligand (Berg et al 1991; Rossiter et al 1994). However, the carbohydrate moieties mediating tethering and rolling of lymphocytes along the endothelial lining also bind to P- and L-selectin (Labow et al 1994; Jung and Ley 1999; Collins et al 2001). Activated endothelial cells in inflamed tissues may express PNAd, a ligand for lymphocyte-expressed L-selectin, although L-selectin itself is not expressed by endothelial cells. This mechanism may compensate for lymphocyte rolling when E- and P-selectin are selectively blocked, e.g., by small-molecule- or antibody-based therapeutics (Alon and Feigelson 2002; Dwir et al 2002). In addition, T cells may roll along the vessel wall through cluster formation with activated platelets (Diacovo et al 1996, 1998; Ludwig et al 2004), and even in the complete absence of selectins and their ligands, rolling of some lymphocytes may occur through interactions of endothelial VCAM-1 with the lymphocyte-expressed VLA-4 integrin (Jung and Ley 1999). Similar problems may be encountered when glycosylation of selectin ligands is targeted, e.g., by proteasome inhibitors (Zollner et al 2002). Rational drug design of compounds modeled after functionally relevant groups, or high-throughput screenings assessing the functions of single molecules as readout parameters might, therefore, confront the aforesaid problems.

Recent examples of approaches that may have been too specific (thus neglecting functional redundancy) include the failure of antibodies directed specifically against E-selectin or L-selectin to alleviate psoriasis in controlled clinical trials (Bhushan et al 2002; Hardtke et al 2005), or the limited clinical response to recombinant human (rh) PSGL-1 Ig (Khor et al 2000). In that respect, concepts interfering with a group of molecules with overlapping functions involved in a given step of lymphocyte extravasation may bear some advantages, such as efomycine M or the TBC-1269 compound (bimosiamose) blocking several selectins (Abraham et al 1999; Schön et al 2002). However, the success of such broader strategies is not guaranteed, as exemplified by the insufficient response to the pan-selectin inhibitor OJ-R9188 (Ikegami-Kuzuhara et al 2001).

Another group of potential problems relates to unexpected effects; i.e., targeting of certain molecules may result in unexpected or even paradoxical outcomes. As a possible example, a regulatory effect of chemokines on lymphocyte rolling has recently been identified, inasmuch as chemokines may exert paradoxical antiadhesive effects through G-protein-independent destabilization of L-selectin (Grabovsky et al 2002).

An alternative or additional approach to target leukocyte rolling along the skin microvasculature through modulation of selectin functions is interference with fucosyltransferase-(FucT)-VII and -IV, key enzymes in the generation of selectin-ligand carbohydrate moieties. The rationale behind this approach comes from the observation that selectin ligand activity is absent or reduced dramatically in FucT-VII single or FucT-IV and -VII double knockout mice. Cutaneous inflammatory responses are markedly reduced in several models of inflammatory diseases using animals deficient for one or both enzymes (Maly et al 1996; Weninger et al 2000; Homeister et al 2001; Asadullah et al 2002). The relevance of this impaired function in human patients is highlighted by leukocyte adhesion deficiency II (LAD II), a rare congenital immune defect (Gu et al 2004). One potential approach to interfere with expression of FucT-VII is inhibiting its transcription using NF-κB inhibitors such as the proteasome inhibitor PS-519 or antioxidants such as N-acetyl cysteine (Zollner et al 2002). However, given that interfering with the pleiotropic effects of NF-κB may have many other effects on the immune system and other cells, the low specificity of this approach is a potential disadvantage. Another strategy might encompass the inhibition of FucT activity by small-molecule compounds. As posttranslational glycosylation of proteins by FucTs occurs in the Golgi apparatus, it might, however, be challenging to identify small molecules penetrating both the
cell membrane and the Golgi membrane. At least two different companies (GlaxoSmithKline, Kyowa Hakko Kogyo) have reported recombinant expression of FucT-VII protein (Shinkai et al 1997; Smithers et al 1997), suggesting that this latter approach has been pursued. In addition, panosialins A and B have been isolated as inhibitors of FucT-VII from the culture broth of Streptomyces sp., which inhibit FucT-VII activity and cell binding to immobilized selectin ligands in vitro (Shinoda et al 1998).

Overall, it is generally not easy to predict the clinical feasibility and efficacy of selectively targeting selectin functions in the treatment of inflammatory disorders. It appears that at least two levels of complex interactions influence the success of therapeutic strategies aimed at lymphocyte extravasation; ie, distinct players mediating consecutive pathogenic steps (“vertical”, eg, chemokine receptor activation followed by integrin-mediated firm arrest), as well as synchronous action of several molecules mediating a given event (“horizontal”, eg, selectins and chemokine receptors simultaneously involved in lymphocyte rolling).

Acknowledgments

This work was supported by a Rudolf Virchow Award from the Deutsche Forschungsgemeinschaft to MPS.

References

Abraham WM, Ahmed A, Sabater JR, et al. 1999. Selectin blockade prevents antigen-induced late bronchial responses and airway hyperresponsiveness in allergic sheep. *Am J Respir Crit Care Med*, 159:1205–14.

Alan R, Chen S, Fuhrigge R, et al. 1998. The kinetics and shear threshold of transient and rolling interactions of L-selectin with its ligand on lymphocytes. *Proc Natl Acad Sci U S A*, 95:11631–6.

Alan R, Feigelson S. 2002. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. *Semin Immunol*, 14:93–104.

Anaya-Prado R, Ramos-Kelly JR, Toledo-Pereyra LH, et al. 2002. Multiple selectin blockade with a small-molecule selectin inhibitor does not affect survival after a second inflammatory challenge with nonlethal LPS. *J Invest Surg*, 15:171–80.

Asadullah K, Lowe JB, Schottelius A. 2002. Differential influences on FucT-VII activity and cell binding to immobilized selectin ligands from the culture broth of Streptomyces sp., which inhibit FucT-VII activity and cell binding to immobilized selectin ligands in vitro (Shinoda et al 1998).

Berg EL, Yoshino T, Rott LS, et al. 1991. The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule-1. *J Exp Med*, 174:1461–6.

Berg C, Bargatze RF, Campbell JJ, et al. 1995. Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. *Cell*, 80:413–22.

Bevilacqua MP, Stengelin S. 1989. Endothelial leukocyte adhesion molecule-1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. *Science*, 243:1160–3.

Bhushan M, Bleker TO, Ballsdon AE, et al. 2002. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. *Br J Dermatol*, 146:824–31.

Biedermann T, Schwärzler C, Lametschwandtner G, et al. 2002. Targeting CLA-E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo. *Eur J Immunol*, 32:3171–80.

Birnbaum Y, Patterson M, Kloner RA. 1997. The effect of CY-1503, a sialyl LewisX analog blocker of the selectin adhesion molecules, on infant size and “no reflow” in the rabbit model of acute infarction/ reperfusion. *J Mol Cell Cardiol*, 29:2013–25.

Binzer U, Issakutz TB, Walter U, et al. 2000. The role of alpha(4) and LFA-1 integrins in selectin-independent monocyte and neutrophil migration to joints of rats with adjuvant arthritis. *Int Immunol*, 12:141–50.

Boehncke WH, Schön MP. 2003. Interfering with leukocyte rolling – a promising therapeutic approach in inflammatory skin disorders? *Trends Pharmacol Sci*, 24:49–52.

Bonfanti R, Furies BC. 1989. PADGEM (GMP140) is a component of Waibel-Palade bodies of human endothelial cells. *Blood*, 73:1109–12.

Butcher EC, Picker LJ. 1996. Lymphocyte homing and homeostasis. *Science*, 272:60–6.

Carlos TM, Harlan JM. 1994. Leukocyte-endothelial adhesion molecules. *Blood*, 84:2068–101.

Carraway MS, Welty-Wolf KE, Kantom SP, et al. 1998. Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons. *Am J Respir Crit Care Med*, 157:938–49.

Collins RG, Jung U, Ramirez M, et al. 2001. Dermal and pulmonary inflammatory disease in E-selectin and P-selectin double-null mice is reduced in triple-selectin-null mice. *Blood*, 98:727–35.

Condon TP, Flourney S, Sawyer JJ, et al. 2001. ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. *Antisense Nucleic Acid Drug Dev*, 11:107–16.

Cotran RS, Gimbrone MAJ. 1986. Induction and detection of a human endothelial activation antigen in vivo. *J Exp Med*, 164:661–6.

Diacono TG, Catalina MD, Siegelman MH, et al. 1998. Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. *J Exp Med*, 187:197–204.

Diacono TG, Pur K, Warkner RA, et al. 1996. Platelet-mediated lymphocyte delivery to high endothelial venules. *Science*, 273:252–5.

Dwirt O, Steeber DA, Schwarz US, et al. 2002. L-selectin dimerization enhances tether formation to properly spaced ligand. *J Biol Chem*, 277:21130–9.

Feigelson SW, Grabovsky V, Winter E, et al. 2001. The Src kinase p56(lck) up-regulates VLA-4 integrin affinity. Implications for rapid spontaneous and chemokine-triggered T cell adhesion to VCAM-1 and fibronectin. *J Biol Chem*, 276:13891–901.

Feizi T. 2001. Carbohydrate ligands for the leukocyte-endothelium adhesion molecules, selectins. *Results Probl Cell Differ*, 33:201–23.

Fong AM, Robinson LA, Steeber DA, et al. 1998. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. *J Exp Med*, 188:1413–19.

Fors BP, Goodarzi K, von Andrian UH. 2001. L-selectin shedding is independent of its subsurface structures and topographic distribution. *J Immunol*, 167:3642–51.
Springer TA. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell, 76:301–14.
Thomson AW, Nalesnik MA, Rilo HR, et al. 1993. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. Autoimmunity, 15:215–23.
Todderud G, Nair X, Lee D, et al. 1997. BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions. J Pharmacol Exp Ther, 282:1298–304.
Ulbrich H, Eriksson EE, Lindbom L. 2003. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci, 24:640–7.
Varki A. 1994. Selectin ligands. Proc Natl Acad Sci U S A, 91:7390–7.
von Andrian UH, Chambers JD, McEvoy LM, et al. 1991. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta-2 integrins in vivo. Proc Natl Acad Sci U S A, 88:7538–42.
von Andrian UH, Mackay CR. 2000. T-cell function and migration. Two sides of the same coin. N Engl J Med, 343:1020–34.
von Andrian UH, Mempel TR. 2003. Homing and cellular traffic in lymph nodes. Nat Rev Immunol, 3:867–78.
Weninger W, Ulfman LH, Cheng G, et al. 2000. Specialized contributions by alpha(1,3)fucosyltransferase-IV and Fuc-TVII during leukocyte rolling in dermal microvessels. Immunity, 12:665–76.
Yvin JC, Alban S, Franz G. 2002. Anti-inflammatory and healing medicine based on laminarin sulphate. In PCT Int Appl Patent nr. WO 2002036132 (10.05.2002): France.
Zhao LC, Edgar JB, Dailey MO. 2001. Characterization of the rapid proteolytic shedding of murine L-selectin. Dev Immunol, 8:267–77.
Zlotnik A, Yoshie O. 2000. Chemokines: a new classification system and their role in immunity. Immunity, 12:121–7.
Zollner TM, Podda M, Pien C, et al. 2002. Proteosome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest, 109:671–9.